FDA Application for Orphan Drug Designation , PAA, MPL, page-62

"...................The question should be why the directors shut shop rather than try sale.........................."

I wonder if the feedback from shell on the OHD project was a flop? We were probably coming around to that time when they had to stump up another $250K or whatever for the annual licensing fee. I think we were tied into a 5 year contract for this fee whether we got an income or not. If the Shell feedback was a rejection then why pay for another year and have to explain to SHs what had gone wrong. We still haven't been updated by the way, which I find a bit rude. The BoD likely decided to clear the decks and focus on MND with no nasty HR issues at Epichem to deal with. Winding them up probably gave a free hand to whoever has taken over (it better not be Shell !) to clear out the dead wood and concentrate on the productive members of the team. It will be interesting to see how they evolve without PAA making the rules.